Journals / GORM:Gynecology Obstetrics & Reproductive Medicine / 2012 / Cilt: 18 - Sayı: 3

Gastrointestinal Stromal Tumor Mimicking Ovarian Tumor

Pages
52–54
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Histopathological examinations should be performed by experi- enced pathologists

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Malignant gastrointestinal stromal tumors are rare mesenchymal tumors originating from the gastroin- testinal tract.
📊
Key Findings & Data:The patient was a 45- year-old woman who presented to our clinic with a palpable mass fill- ing the pelvis.
💡
Conclusion & Impact:Histopathological examinations should be performed by experi- enced pathologists
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Malignant gastrointestinal stromal tumors are rare mesenchymal tumors originating from the gastroin- testinal tract. Making a differential diagnosis with gynecologic masses may be difficult in the preopera- tive period. The patient was a 45- year-old woman who presented to our clinic with a palpable mass fill- ing the pelvis. The CA 125 value was 42.7 U/ml. She underwent right hemicolectomy, total omentectomy, total abdominal hysterectomy, bilateral salpingo-oophorectomy and bilateral pelvic and para-aortic lymph node dissection since the frozen section assessment of the biopsy from the right colon was re- ported as a tumoral mass probably originating from the ovary. Tumoral tissue showed diffuse cytoplas- mic membraneous staining immunohistochemically with CD117, showed strong focal strong cytoplasmic staining with SMA. It was stained negative with desmin, S-100 and CD34. Molecular analysis of KIT gene was performed, we didn't detect mutations of exon 9 or 11. Surgical exploration of pelvic masses with undetermined origins should be performed in multidiciplinary hospitals including gynecological on- cology and surgical oncology teams. Histopathological examinations should be performed by experi- enced pathologists

🔖

Cite This Article

KERİMOĞLU, Ö. S., BABA, F., TAZEGÜL, A., ALPTEKİN, H., ACAR, H., ÇELİK, Ç. (2012). Gastrointestinal Stromal Tumor Mimicking Ovarian Tumor. GORM:Gynecology Obstetrics & Reproductive Medicine, Cilt: 18 - Sayı: 3, 52–54. https://ajindex.com/articles/214239

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Carlomagno G, Beneduce P: A gastrointestinal stromal tumor (GIST) masquerading as an ovarian mass. World J Surg Oncol 2004:13;2:15
  2. Davies M, Crosbie EJ, Mamtora H, Verma S, Formela L, Slade RJ: Gastrointestinal stromal tumour presenting as an ovarian tumour. J Obstet Gynaecol 2010;30:324-5. 3. de Silva CM, Reid R: Gastrointestinal stromal tumors (GIST): C-kit mutations, CD117 expression, differential diagnosis and targeted cancer therapy with Imatinib. Pathol Oncol Res 2003;9:13-9
  3. Pidhorecky I, Cheney RT, Kraybill WG, Gibbs JF: Gastrointestinal stromal tumors: current diagnosis, biologic behavior, and management. Ann Surg Oncol 2000; 7:705-12
  4. DeMatteo RP: The GIST of targeted cancer therapy: a tumor (gastrointestinal stromal tumor), a mutated gene (ckit), and a molecular inhibitor (ST1571). Ann Surg Oncol 2002;9:831-9
  5. Medeiros F, Corless CL, Duensing A, et al. KIT-negative gastrointestinal stromal tumors: prof of concept and therapeutic implications. Am J Surg Pathol 2004;28:889-94
  6. Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003;299:708-10
  7. Hirota S, Ohashi A, Nishida T, et al. Gain-of-function mutations of platelet-derived growth factor receptor α gene in gastrointestinal stromal tumors. Gastroenterology 2003; 125:660-7
  8. Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: Randomised trial. Lancet 2004;364:1127-34
  9. Heinrich MC, Owzar K, Corless CL, et al. Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol 2008;20: 5360-7
  10. Debiec-Rychter M, Sciot R, Le CA, et al: KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 2006;42:1093-1103.